Compare ATEN & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEN | TBPH |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2014 | N/A |
| Metric | ATEN | TBPH |
|---|---|---|
| Price | $20.60 | $19.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $22.67 | ★ $27.80 |
| AVG Volume (30 Days) | ★ 921.6K | 368.8K |
| Earning Date | 02-04-2026 | 02-23-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.57 | ★ 0.58 |
| Revenue | ★ $290,557,000.00 | $80,327,000.00 |
| Revenue This Year | $9.40 | $70.90 |
| Revenue Next Year | $7.65 | N/A |
| P/E Ratio | $36.32 | ★ $33.66 |
| Revenue Growth | 11.03 | ★ 27.12 |
| 52 Week Low | $13.81 | $7.90 |
| 52 Week High | $21.90 | $21.03 |
| Indicator | ATEN | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 66.40 | 50.55 |
| Support Level | $20.17 | $18.45 |
| Resistance Level | $21.31 | $19.71 |
| Average True Range (ATR) | 0.78 | 0.80 |
| MACD | 0.29 | -0.10 |
| Stochastic Oscillator | 79.60 | 51.63 |
A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).